Physician profile
Daniel S May
NPI 1386652683
$3,599.92
in general payments reported to CMS, 2019-2025
20 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.07 · 2020: $173 · 2021: $404 · 2022: $390 · 2023: $564 · 2024: $960 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.83 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $745.59 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $378.50 | 2021-2025 | Qelbree |
| Tris Pharma INC | $362.50 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Collegium Pharmaceutical, INC. | $301.55 | 2025 | Jornay Pm |
| Pfizer INC. | $290.81 | 2020-2024 | |
| Adlon Therapeutics L.P. | $249.03 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $221.64 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $197.28 | 2022-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $176.05 | 2020-2025 | Bexsero, Penmenvy, Pediarix |
| Ars Pharmaceuticals Operations, INC. | $141.29 | 2025 | Neffy |
| Cranial Technologies, INC | $138.81 | 2021-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $83.49 | 2024-2025 | Vaxneuvance, Vaxelis, Rotateq |
| Seqirus USA INC | $78.69 | 2024-2025 | Flucelvax, Fluad |
| Alk-Abello, INC | $56.50 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $52.16 | 2024-2025 | Ycanth |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $37.78 | 2024-2025 | Relexxii |
| Sanofi Pasteur INC. | $36.27 | 2021-2023 | |
| Genentech USA, INC. | $21.13 | 2020 | |
| Phadia US INC. | $16.96 | 2025 | Immunocap |
| Mission Pharmacal Company | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.